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Abstract
Objective—Conduct a representative survey of Human papillomavirus (HPV) prevalence and its 
genotype distribution in invasive anal cancer specimens in the U.S.
Methods—Population-based archival anal cancer specimens were identified from Florida, 
Kentucky, Louisiana and Michigan cancer registries and SEER tissue repositories in Hawaii, Iowa 
and Los Angeles. Sections from one representative block per case were used for DNA extraction. 
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All extracts were assayed first by Linear Array and re-tested with INNO-LiPA if inadequate or 
HPV negative.
Results—Among 146 unique invasive anal cancer cases, 93 (63.7%) were from women and 53 
(36.3%) from men. HPV (any type) was detected in 133 (91.1%) cases and 129 (88.4%) contained 
at least one high risk type, most (80.1%) as a single genotype. HPV16 had the highest prevalence 
(113 cases, 77.4%); HPV6, 11, 18 and 33 were also found multiple times. Among HPV16 positive 
cases, 37% were identified as prototype variant Ep and 63% were non-prototypes: 33% Em, 12% 
E-G131G, 5% Af1, 4% AA/NA-1, 3% E-C109G, 3% E-G131T, 2% As and 1% Af2. No 
significant differences in the distributions of HPV (any), high-risk types, or HPV16/18 were seen 
between gender, race or age group.
Conclusions—The establishment of pre-vaccine HPV prevalence in the U.S. is critical to the 
surveillance of vaccine efficacy. Almost 80% of anal cancers were positive for the vaccine types 
HPV16 or HPV18 and in 70% these were the only types detected suggesting that a high proportion 
might be preventable by current vaccines.
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Introduction
Anal cancers are relatively rare malignancies, most of which occur as squamous cell 
carcinomas (SCC) of the anal tract. According to 2009 NPCR/SEER combined data, the 
incident rate for invasive anal cancer in the U.S. was 1.8 per 100,000, totaling 2236 cases in 
males (rate 1.5) and 3692 among females (rate 2.1) annually (1). While incidence is 
relatively low, the number of anal malignancies has steadily increased over the past three 
decades (2). Many of the recognized risk factors for anal cancer, such as number of sexual 
partners and anal receptive intercourse, are associated with persistent human papillomavirus 
(HPV) infection of the anal canal (3;4). Anal histology shares common anatomic 
characteristics with the cervix, including a transformation zone where most HPV-associated 
neoplastic transformation occurs. It is therefore anticipated that available HPV vaccines will 
provide protection against anal cancer too and clinical trials of the quadrivalent Gardasil 
(Merck & Co, Inc., Whitehouse Station, NJ) showed good efficacy against anal 
intraepithelial neoplasia (5;6).
The proportion of anal carcinomas attributable to HPV has been estimated to be about 90% 
(7–9) attributing the majority to HPV16 and HPV18. However, no population-based data are 
available for the United States regarding the type-specific HPV prevalence in anal cancers 
preceding vaccine implementation. Such information will provide a baseline to monitor 
vaccine effectiveness against this malignancy. To meet this surveillance objective, 
population-based sampling of anal cancer tissue from US central state registries was 
conducted to determine the type-specific HPV prevalence in these cases.
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HPV 16 cases were further evaluated to determine HPV16 genotype variants since some 
reports had indicated that certain non-prototype sequences have a disproportionally high 
representation in anal diseases (10;11).
Materials and Methods
Selection of anal cancer tissues
Representative tissue specimens were obtained as part of the Centers for Disease Control 
Central Cancer Registries (CDC CCR) study to provide a baseline prevalence of HPV types 
in HPV-associated cancers from a representative sample of the US population. A systematic 
full case selection of anatomic regions coded as anal canal was pursued depending on 
specimen availability. Cases were recruited from seven participating registries, including 
four central cancer registries (CCRs) in Florida, Kentucky, Louisiana and Michigan as well 
as three SEER cancer registry-based residual tissue repositories (RTRs) in Los Angeles 
County, Hawaii and Iowa. CCR associated pathology laboratories and RTRs were asked to 
select one representative archived, formalin-fixed paraffin-embedded (FFPE) tissue block 
from each anal cancer case that was diagnosed between 1995 and 2005. CDC and each 
participating state received approval from the Institutional Review Board (IRB) for the 
study.
Specimen preparation and DNA extraction
Six microtome sections were prepared from each block using a fresh disposable blade and 
applicator for each case. The first and last sections were stained with Hematoxylin and Eosin 
(H&E) and intervening sections - two 5-µm sections per sample - were transferred into 2 ml 
conical screw cap tubes with tether cap (Simport, Beloeil, Canada). H&E sections were 
reviewed by a study pathologist (ERU) to confirm that the sections included viable tumor. 
Cases that did not have representative material were excluded; otherwise samples were 
processed as previously described using high temperature-assisted tissue lysis (12) and 
automated DNA purification with a Chemagic MSM1 (PerkinElmer, Waltham, MA, USA). 
The resulting 100 µL DNA eluate was tested immediately or stored at −20°C. A blank 
sample without tissue was included in every extraction batch to monitor potential cross 
contamination.
HPV Genotyping
All extracts were tested with the Linear Array HPV Genotyping Test (LA, Roche 
Diagnostics, Indianapolis, IN), which distinguishes 37 different HPV genotypes (6, 11, 16, 
18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52(XR), 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 
69, 70, 71, 72, 73, 81, 82, 83, 84, 89, IS39). Templates for the PCR reaction were prepared 
with 10 µl DNA and 40 µl H2O, otherwise following the manufacturer’s protocol. The 
reverse line blot hybridization was performed with an automated platform (Beeblot 
instruments (Bee Robotics, Caernarfon, UK)). Samples with negative or inadequate 
(negative for HPV and cellular β-Globin control) LA results were re-tested with the INNO-
LiPA HPV Genotyping Assay (LiPA, Innogenetics, Gent, Belgium) which detects 29 HPV 
types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69, 
70, 71, 73, 74, 81, 82). The assay was performed according to the manufacturers 
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specifications using an Autoblot 3000 (MedTec, Buffalo Grove, IL) for the line-blot 
procedure.
HPV16 variant determination
All samples positive for HPV16 by either LA or LiPA genotyping assays were subjected to 
variant analysis with a pyrosequencing assay (13). Briefly, 10 µl of the extracted DNA was 
used as a template to amplify a 314 bp fragment of the E6 region. If no amplicon was visible 
by gel electrophoresis, the procedure was repeated with an enriched template that was first 
amplified by whole genome amplification with the GenomePlex WGA2 kit (Sigma-Aldrich, 
St Louis, MO, USA) in accordance with the manufacturer’s recommendations. 
Subsequently, nucleotide identities at position 109, 131, 132, 143, 145, 178, 350 were 
determined with a Pyromark Q96 MD (Qiagen, Valencia, CA, USA) to identify the variants 
AA/NA-1, Af1, Af2, As, E-C109G, E-G131G, E-G350, Em, Ep. In cases, where the pyro 
signals were ambiguous, the E6 amplicon was also sequenced by the traditional Sanger 
method as described previously (14).
Analysis
Prevalence was consistently calculated as percentage of positives from the total number of 
cases tested. HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were 
considered high-risk (hr) with regards to oncogenic potential (15) and all other types as low-
risk. Differences in prevalence for any HPV type, hr HPV positive or HPV16 and 18 
positive by gender, race, age, and disease stage were evaluated using Fisher’s Exact Test. 
Age was grouped into 10-year intervals. Cancer stage was crudely classified as local, 
regional, distant, or unknown, and termed SEER stage.
Hierarchical categories for HPV status were assigned as follows: (1) HPV16 – includes all 
cases positive for this type regardless of other results, (2) HPV18 - adds all case positive for 
HPV18, but not for HPV16, (3) other hr HPV – adds cases positive for any high risk type as 
listed above, but not HPV16 or 18, (4) any HPV – adds all cases positive for any HPV type 
not included in the previous groups.
Results
Within the time period between 1995 and 2005, a total of 401 eligible anal cancer cases 
were identified from the records of the seven registries and RTRs. Due to lack of availability 
or participation tissues were not received from 222 cases. An additional 32 cases were 
excluded for insufficient malignant representation and one sample was inadequate in HPV 
testing. Despite this reduction, the admitted tissue samples appeared to be representative of 
cancers diagnosed in participating registries, based on demographic variables such as age, 
race, and sex (data not shown).
Specimens from the remaining 146 anal cancer cases were successfully tested. The patient’s 
gender, race and age were distributed as shown in Table 1. HPV genotyping results were 
obtained by LA from 127 cases and by LiPA for the remaining 19. Any HPV was detected 
in 133 (91.1%) cases. A high risk-type was found in 129 cases (88.4%) and four (2.7%) 
contained only low risk HPV (two each with HPV6 and HPV26). In 117 (80.1%) cases a 
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single HPV infection was detected. Multiple types (2 – 6) were observed in 16 (11%) cases 
averaging 1.17 types per positive sample. HPV16 was present in 113 (77.4%) cases, HPV18 
in 5 (3.4%) and two of them (1.4%) had both of these types. Other frequently identified 
types included HPV33 (9 cases, 6.2%), as well as HPV6 (6 cases, 4.1%) and 11 (5 cases, 
3.4%) (see Table 2 for further details).
By histological type, hr HPV types were found in 126 of 133 (94.7%) squamous cell 
carcinomas (SCC), in 2 of 11 (18.2%) adenocarcinomas (both HPV16) and in one of the 
tumors with “other” histology (HPV31). Applying hierarchical assignment, 113 anal cancers 
(77.4%) were attributable to HPV16, an additional 3 (2.1%) to HPV18, a further 13 (8.9%) 
to all other high risk types, and 4 (2.7%) to all remaining HPV types (Fig. 1). Proportions of 
cases positive for HPV (any type tested), hr HPV or HPV16/18 were not statistically 
different by sex, race, age group, or SEER stage (Table 1).
Pyrosequencing allowed determination of HPV 16 variant lineage in 98 HPV16 positive 
cases. An additional 2 were clarified by Sanger sequencing. For the remaining 13, PCR 
amplification or sequencing could not be achieved at a quality necessary for unambiguous 
variant typing. As detailed in Table 3, the majority of HPV16 variants were European (88%) 
followed by African and Asian variants (6% each).
Discussion
The tissues obtained for this study were requested from seven state cancer registries and 
provide the first U.S. population-based assessment of HPV prevalence and type distribution 
in anal cancers. As expected, HPV prevalence was high and at least one hr type was found in 
almost 90% of the anal cancer cases. Internationally, findings have varied substantially, 
likely a result of small sample sizes, as well as disparate HPV detection methodologies and 
sensitivity. Nonetheless, most studies based on consensus primer PCR systems also have 
reported HPV prevalence in anal cancer tissue of 80% or greater (3;16;17). While the 
combined use of the LA and LiPA HPV genotyping tests has potentially increased overall 
detection sensitivity in our study, the type-specific prevalence was similar to that reported in 
a meta-analysis including North American studies mainly among MSM (3), where over 70% 
were HPV16-positive and prevalence of HPV6, 18 and 33 were observed at 5 and 10% each. 
It is unclear if the remaining small proportion of anal cancer specimens are HPV negative as 
a result of sampling artifact, deficiencies in the HPV detection methodology, or if these 
cases were truly triggered by alternative carcinogenic agents. By histological examination, 
only 4 of the 13 HPV negative tumors were squamous carcinomas. The rest were 
adenocarcinomas that could be of colorectal origin (7), Paget’s disease (1) or 
undifferentiated (1).
No evidence was found for differences in HPV prevalence between any of the demographic 
subgroups or cancer stage included in the analysis. This was not surprising considering the 
high HPV prevalence, especially for HPV16, and the modest size of the study population.
Distribution of HVP16 variants was dominated by European lineages and was very similar 
to results found in cervical cytology samples in the United States (18). The frequency of the 
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HPV16 G131 variants in our invasive anal tumors was 2.5-fold greater than that reported by 
Da Costa et al. (10) in anal neoplasia tissue from a mostly HIV positive population, which 
may support their hypothesis that infection with the E-G131G or E-G131T genotypes pose 
elevated risk for malignant progression. It is not known if HIV infection plays any role in 
this regard and information on HIV status was not collected in our study.
This study represents the first assessment of HPV type distribution in anal cancers derived 
from a random sample of population based U.S. cancer registries representing different 
geographical regions. HPV16 and HPV18 DNA were found in almost 80% of the anal 
cancers in this study, and 103 anal cancers (70%) were exclusively positive for these two 
types. These results will assist in the establishment of a baseline for etiologic fractions of 
anal cancer attributable to specific HPV genotypes. The data will be integral to the 
surveillance and evaluation of prophylactic HPV vaccine efficacy for anal cancer in the 
United States.
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Hierarchical attribution of HPV types to anal cancers. White fields indicating attribution of 
the specific type or group and black the cumulative prevalence of types with higher 
hierarchy.
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Table 2
Summary of HPV detection in anal cancers
Adequate, eligible samples 146
HPV positive (any type) 133 91.1%
High Riska only 116 79.5%
Low Riskb only 4 2.7%
High and low risk 13 8.9%
Single type 117 80.1%












Other types (one case each) 8 5.5%
a
HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68
b
any HPV not included in the high risk HPV types
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Table 3
Variants determined in 100 HPV16 positive anal cancers











100 of 113 HPV16 positive anal cancer specimens were successfully sequenced, the remaining 13 did not yield data at sufficient quality.
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